- Stocks
- Healthcare
- NYSE: BSX

Price (delayed)

$39.31

Market cap

$55.01B

P/E Ratio

12.76

Dividend/share

N/A

EPS

$3.08

Enterprise value

$64.97B

The P/E is 57% below the last 4 quarters average of 29.5

The equity has grown by 50% YoY

Boston Scientific's net income has surged by 139% YoY but it has decreased by 9% QoQ

The EPS has soared by 137% YoY but it has decreased by 9% from the previous quarter

Boston Scientific's debt has increased by 12% YoY and by 3.3% QoQ

What are the main financial stats of BSX

Market
Valuations
Earnings

Shares outstanding

1.4B

Market cap

$55.01B

Enterprise value

$64.97B

Price to earnings (P/E)

12.76

Price to book (P/B)

3.98

Price to sales (P/S)

5.09

EV/EBIT

92.29

EV/EBITDA

37.89

EV/Sales

6.02

Revenue

$10.79B

EBIT

$704M

EBITDA

$1.72B

Free cash flow

$919M

Per share
Balance sheet
Liquidity

EPS

$3.08

Free cash flow per share

$0.66

Book value per share

$9.89

Revenue per share

$7.72

TBVPS

$9.03

Total assets

$30.11B

Total liabilities

$16.31B

Debt

$10.34B

Equity

$13.8B

Working capital

$847M

Debt to equity

0.75

Current ratio

1.21

Quick ratio

0.49

Net debt/EBITDA

5.81

Margins
Efficiency
Dividend

EBITDA margin

15.9%

Gross margin

70.4%

Net margin

39.7%

Operating margin

10.4%

Return on assets

15.3%

Return on equity

36.6%

Return on invested capital

4.3%

Return on capital employed

2.7%

Return on sales

6.5%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Boston Scientific stock price performed over time

How have Boston Scientific's revenue and profit performed over time

Revenue

$10.79B

Gross profit

$7.59B

Operating income

$1.12B

Net income

$4.29B

Gross margin

70.4%

Net margin

39.7%

Boston Scientific's net income has surged by 139% YoY but it has decreased by 9% QoQ

Boston Scientific's net margin has surged by 119% YoY but it has decreased by 9% QoQ

BSX's operating margin is down by 37% year-on-year and by 26% since the previous quarter

Boston Scientific's operating income has decreased by 32% YoY and by 26% from the previous quarter

What is Boston Scientific stock price valuation

P/E

12.76

P/B

3.98

P/S

5.09

EV/EBIT

92.29

EV/EBITDA

37.89

EV/Sales

6.02

The EPS has soared by 137% YoY but it has decreased by 9% from the previous quarter

The P/E is 57% below the last 4 quarters average of 29.5

The equity has grown by 50% YoY

The stock's price to book (P/B) is 20% less than its 5-year quarterly average of 5.0 and 20% less than its last 4 quarters average of 5.0

BSX's P/S is 16% above its 5-year quarterly average of 4.4 but 6% below its last 4 quarters average of 5.4

The revenue has increased by 9% YoY

How efficient is Boston Scientific business performance

The return on assets has surged by 80% year-on-year but it has declined by 14% since the previous quarter

BSX's ROIC has plunged by 78% YoY and by 44% from the previous quarter

The return on equity has surged by 74% year-on-year but it has declined by 18% since the previous quarter

The ROS has plunged by 65% YoY and by 40% from the previous quarter

What is BSX's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for BSX.

How did Boston Scientific financials performed over time

Boston Scientific's total assets is 85% more than its total liabilities

BSX's quick ratio is up by 26% year-on-year and by 17% since the previous quarter

BSX's current ratio is up by 25% since the previous quarter but it is down by 13% year-on-year

Boston Scientific's debt is 25% lower than its equity

Boston Scientific's debt to equity has decreased by 25% YoY but it has increased by 4.2% from the previous quarter

Boston Scientific's debt has increased by 12% YoY and by 3.3% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.